Emerging treatments

Ixazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…

Complications of myeloma and its treatments

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…

Emerging treatments

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Armoiry X et al. Pharmacoeconomics. 2018 Sep. doi: 10.1007/s40273-018-0644-3. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Sep. doi: 10.1007/s00520-018-4165-6. Surgical thyroparathyroidectomy…

Diagnostic techniques and prognostic indicators

The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Jiang Yet al. Oncol Lett. 2018 Sep. doi: 10.3892/ol.2018.9128. [Epub 2018 Jul 11] Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Stolzenburg A et al. Eur J Nucl Med Mol Imaging. 2018 Sep. doi: 10.1007/s00259-018-3997-0. Determining treatment intensity…

Current treatments

Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.] Proteasome inhibitors for multiple myeloma. Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.…

Biology and Genetics

miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27] Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544.…